What is it about?
About the present role of palbociclib - the first in this class CDK4/6 inhibitor-, in the treatment of ER+ve/HER2-ve locally advanced and metastatic breast cancer
Featured Image
Why is it important?
Represents a new therapeutic option
Perspectives
The development of CDK4/6 inhibitors and the introduction of palbociclib into clinical practice, represent an important addition to the therapeutic armamentarium in metastatic breast. There are several therapeutic choices available for ER+ve/HER2-ve advanced breast cancer, but adding palbociclib to hormone therapy is an option with strong efficacy data.
MD,PhD Katalin BK Boér
Szent Margaret Hospital
Read the Original
This page is a summary of: Impact of palbociclib combinations on treatment of advanced estrogen receptor-positive/human epidermal growth factor 2-negative breast cancer, OncoTargets and Therapy, October 2016, Dove Medical Press,
DOI: 10.2147/ott.s77033.
You can read the full text:
Contributors
The following have contributed to this page
